本页面由Tiger Trade Technology Pte. Ltd.提供服务

Scinai Immunotherapeutics Ltd.

0.5550
-0.0450-7.50%
盘后0.55780.0028+0.50%19:36 EDT
成交量:7.03万
成交额:3.96万
市值:196.22万
市盈率:-0.16
高:0.6298
开:0.6000
低:0.5406
收:0.6000
52周最高:6.18
52周最低:0.5406
股本:353.55万
流通股本:312.89万
量比:4.95
换手率:2.25%
股息:- -
股息率:- -
每股收益(TTM):-3.5578
每股收益(LYR):5.95
净资产收益率:-91.89%
总资产收益率:-37.60%
市净率:0.79
市盈率(LYR):0.09

数据加载中...

2026/04/01

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2025/11/12

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/09/30

SEC问询函

Form CORRESP - Correspondence
2025/09/22

招股说明书

Form F-1 - Registration statement for certain foreign private issuers
2025/05/07

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2025/03/12

SEC问询函

Form CORRESP - Correspondence
2025/03/11

[修订]招股说明书

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2025/03/04

招股说明书

Form F-1 - Registration statement for certain foreign private issuers
2024/11/14

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/08/20

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/05/15

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/03/12

超过5%披露

Form SC 13D - General statement of acquisition of beneficial ownership
2024/02/14

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/09

SEC问询函

Form CORRESP - Correspondence
2024/01/25

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2023/12/26

SEC问询函

Form CORRESP - Correspondence
2023/12/22

[修订]招股说明书

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2023/10/31

招股说明书

Form F-1 - Registration statement for certain foreign private issuers
2023/08/23

SEC问询函

Form CORRESP - Correspondence
2023/06/08

重要事件披露

Form 8-K - Current report